🔎 Trials Near Me

Home › Wilms Tumor › Texas

Pag-aaral pangklinika para sa Wilms Tumor sa Texas

6 pag-aaral para sa Wilms Tumor ang naghahanap ng mga kalahok sa mga site sa Texas.

Mga Lungsod sa Texas

Opisyal na teksto ng pag-aaral (English)

Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor

  • UT Southwestern/Simmons Cancer Center-Dallas, Dallas
Nagre-recruitPhase 2
Edad 12 hanggang 39 · Lahat ng kasarian · Na-update Set 29, 2026 · NCT04616560

A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT

  • Dell Children's Medical Center of Central Texas, Austin
  • Driscoll Children's Hospital, Corpus Christi
  • Medical City Dallas Hospital, Dallas
  • at 10 pa
Nagre-recruitPhase 2
Hanggang edad 30 · Lahat ng kasarian · Na-update Ago 25, 2026 · NCT04322318

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

  • Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
Nagre-recruitPhase 1/2
12 Months – 30 Years · Lahat ng kasarian · Na-update Ago 25, 2026 · NCT04851119

Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors

  • Texas Children's Hospital, Houston
Nagre-recruitPhase 1
Edad 1 hanggang 21 · Lahat ng kasarian · Na-update Ago 6, 2026 · NCT04715191

A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors

  • Cook Children's Health Care System (Data Collection Only), Fort Worth
Nagre-recruitPhase 2
12 Months · Lahat ng kasarian · Na-update May 6, 2026 · NCT05985161

Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells

  • Houston Methodist Hospital, Houston
Nagre-recruitPhase 1
Hanggang edad 21 · Lahat ng kasarian · Na-update Nob 3, 2025 · NCT06198296

Mula sa ClinicalTrials.gov, na-kuha noong Okt 5, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.